CCO Oncology Podcast

Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Episode Summary

In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, discuss new data and studies in MDS and MPNs presented at ASH 2020.

Episode Notes

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

• 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
• A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
• 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
• Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
• Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.

Presenters:

Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.

Link to full program and Capsule Summary downloadable slidesets:
http://bit.ly/3tyQ9nG